- Home
- Advocacy
- Latest News and Practice Data
- Genomic testing expands under Medicare
The CAP's molecular oncology experts are supporting updates to a Medicare local coverage policy for Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases.
Why it matters: This expands coverage and improves patient access to molecular testing for acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN).
- The policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
What's New: Coverage now includes newly-diagnosed or relapsed AML patients, MDS patients with nondiagnostic assessments, and MPN patients requiring risk stratification or disease monitoring.
Go Deeper: Read more about the CAP's Medicare Coverage Advocacy.